Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31277350 | 1.00 | TAAR1 (0.58) | TAAR1MPOALOX5PTGS2SIGMAR1 | |
| SCHEMBL30118916 | 0.94 | TAAR1 (0.60) | TAAR1MPOALOX5PTGS2SIGMAR1 | |
| SCHEMBL80578 | 0.94 | TAAR1 (0.60) | TAAR1MPOALOX5PTGS2SIGMAR1 | |
| Ethylene Glycol SCHEMBL28055624 | 0.86 | ALOX5 (0.64) | TAAR1MPOALOX5PTGS2 | |
| SCHEMBL29474956 | 0.86 | TAAR1 (0.64) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL852646 | 0.86 | TAAR1 (0.64) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL7831226 | 0.86 | TAAR1 (0.69) | TAAR1MPOSIGMAR1AOC3MTNR1A | |
| SCHEMBL9510542 | 0.84 | ALOX5 (0.53) | ALOX5PTGS2 | |
| SCHEMBL8704875 | 0.83 | MPO (0.69) | TAAR1MPOALOX5PTGS2SIGMAR1 | |
| SCHEMBL581720 | 0.82 | ALOX5 (0.69) | TAAR1MPOALOX5PTGS2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275917-A1 | TOPICAL FOAMABLE PHARMACEUTICAL COMPOSITION | EUROFARMA LABORATORIOS S.A. (BR) | 2025-09-04 | — | — | US | claimed |
| EP-4282418-A9 | FOAMING TOPICAL PHARMACEUTICAL COMPOSITION | Eurofarma Laboratórios S.A. (BR) | 2024-07-17 | — | — | EP | claimed |
| EP-4282418-A1 | FOAMING TOPICAL PHARMACEUTICAL COMPOSITION | Eurofarma Laboratórios S.A. (BR) | 2023-11-29 | — | — | EP | claimed |
| WO-2022119431-A1 | PHARMACEUTICAL COMPOSITION HAVING AN ANALGAESIC AND AN ANTIHISTAMINE FOR TREATING RESPIRATORY DISEASES | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2022-06-09 | — | — | WO | claimed |
| CN-113698813-A | Anti-flooding UV optical fiber coloring ink | 瑞通高分子科技(浙江)有限公司 | 2021-11-26 | — | — | CN | claimed |
| US-9905339-B2 | Conductive film forming method and sintering promoter | ISHIHARA CHEMICAL CO., LTD. (JP) | 2018-02-27 | — | — | US | claimed |
| CN-104303242-B | Conductive film forming method and sintering aid | ISHIHARA CHEMICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | claimed |
| EP-2871645-A1 | METHOD FOR FORMING CONDUCTIVE FILM AND SINTERING PROMOTER | Ishihara Chemical Co., Ltd. (JP) | 2015-05-13 | — | — | EP | claimed |
| US-20150118413-A1 | CONDUCTIVE FILM FORMING METHOD AND SINTERING PROMOTER | ISHIHARA CHEMICAL CO., LTD. (JP) | 2015-04-30 | — | — | US | claimed |
| CN-104303242-A | Method for forming conductive film and sintering promoter | ISHIHARA CHEMICAL CO LTD | 2015-01-21 | — | — | CN | claimed |
| EP-0788349-B1 | LIPOSOME COMPOSITION CONTAINING SELEGILIN | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 2001-09-12 | — | — | EP | claimed |
| US-20250275917-A1 | TOPICAL FOAMABLE PHARMACEUTICAL COMPOSITION | EUROFARMA LABORATORIOS S.A. (BR) | 2025-09-04 | — | — | US | disclosed |
| US-12398168-B2 | Preparation method of a glycoside compound | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2025-08-26 | — | — | US | disclosed |
| CN-119451941-A | Bio-based cyanoacrylate compounds | 博斯蒂克股份公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024177520-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLURALANER, MOXIDECTIN AND PRAZIQUANTEL FOR TREATING PARASITIC INFESTATIONS IN SMALL ANIMALS | AGROVET MARKET S.A. (PE) | 2024-08-29 | — | — | WO | disclosed |
| EP-0514665-A1 | Oil-soluble antioxidant mixture | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1992-11-25 | — | — | EP | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
| US-4233430-A | Anti-solar acrylamide derivative polymers, method of making the same and cosmetic compositions containing the same | L'OREAL (FR) | 1980-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398168-B2 | Preparation method of a glycoside compound | GALE, ST6GAL1, MGAM | TAAR1 4827/4885MPO 413/4885ALOX5 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.